› $150,000,000 verdict in personal injury case
Results of a clinical study announced in New Orleans recently appeared to exonerate Avandia from long-held suspicions that the drug causes adverse cardiovascular events in patients undergoing treatment for diabetes 2. Many doctors and other critics, however, say that the study is flawed and remain unconvinced of the findings. Financial analysts believe the results will likely give GlaxoSmithKline’s one-time blockbuster drug a sales boost.
Consumer watchdog group Public Citizen released a petition on Thursday calling for an immediate ban on GlaxoSmithKline’s diabetes drug Avandia. In a petition addressed to Commissioner Dr. Von Eschenbach of the U.S. Food and Drug Administration, Public Citizen urged the ban based on trial data revealing the drug’s “multiple, serious risks.”
A UK newspaper reported yesterday that drug giant GlaxoSmithKline (GSK) – the second largest pharmaceutical company in the world – will cut 150 or more scientists and support staff positions.
